White House launches TrumpRx.gov with discounted Ozempic, Wegovy and Zepbound prices

The White House launched TrumpRx.gov on the night of Feb. 5, 2026, a government referral site that connects patients to drugmakers' own discount programs rather than selling medicine itself ^[1][2]. The site lists lower monthly cash prices for several GLP-1 medications, including semaglutide (Ozempic, injectable Wegovy and the Wegovy pill) and tirzepatide (Zepbound) ^[1].

The prices listed

According to the White House, monthly prices for Ozempic and injectable Wegovy drop from $1,028 and $1,349 to an average of $350, and as low as $199 depending on dosage ^[1]. The monthly price of the Wegovy pill falls from $1,349 to as low as $149, also depending on dosage ^[1]. Zepbound's monthly price falls from $1,088 to an average of $346 and as low as $299 ^[1].

AJMC, reporting the day before the launch, gave slightly different starting figures: about $1,000 for Ozempic, $1,350 for Wegovy and $1,086 for Zepbound, with an initial price of $150 for FDA-approved oral GLP-1 therapy ^[2]. The Wegovy pill is the 25-mg oral semaglutide, the only FDA-approved GLP-1 pill for weight loss at the time of launch; it is also approved to reduce the risk of major cardiovascular events ^[2].

How the site works

No medications are sold on TrumpRx.gov. Patients are meant to use it as a portal to manufacturers' websites and buy directly from the companies ^[1][2]. Thirteen companies have signed most-favored-nation pricing agreements with the administration and will offer direct-to-consumer sales through the platform: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Genentech, Gilead Sciences, GlaxoSmithKline, Merck & Co., Novartis, Novo Nordisk, Pfizer and Sanofi ^[2].

Payment is cash only. Insurance is not accepted as of the launch, which conflicts with some manufacturers' existing direct-to-consumer programs that do take insurance ^[2].

Why it matters for patients

For people who pay cash for a GLP-1 — because they are uninsured, have a high deductible, or their plan does not cover the drug — the listed prices are far below the list prices cited by the White House ^[1]. But experts cautioned that some Americans could end up paying more by going through the site, because most of the medications listed are already covered by insurance and cheaper generic versions exist for some of them ^[2].

The White House lists a separate category of drugs that are often not covered at all, such as fertility medications. It says Gonal-F falls to as low as $168 per pen, Cetrotide from $316 to $22.50 and Ovidrel from $251 to $84 ^[1]. Whether a TrumpRx purchase would count toward a patient's deductible or out-of-pocket maximum has not been reported.

The White House is asking Congress to pass what it calls the Great Healthcare Plan, which it says would codify the most-favored-nation savings and allow TrumpRx purchases to be covered under health plans ^[1].

What happens next

The White House said additional drugs will be added on a rolling basis as more companies sign pricing agreements, and that it is pursuing further deals ^[1]. No timetable for those additions has been reported.

Eli Lilly has submitted a new drug application to the FDA for orforglipron, an oral GLP-1 that was under study in a phase 3 trial; if approved, its lowest dose would start at $149, according to AJMC ^[2]. An FDA decision date has not been reported. Orforglipron was not FDA-approved at the time of the launch ^[2].

Health policy experts have said the savings will not be realized immediately, or possibly at all, and that the full details of the manufacturer agreements may never be made public — including whether the deals remain in effect after Trump leaves office ^[2]. The total effect on Medicaid is also unclear, and some analysts have raised concerns about reduced investment in new drug development, particularly by small and midsize companies ^[2].